CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences (BXLS), today announced the appointment of Bill Meury as CEO and member of the board of directors.

马萨诸塞州剑桥，2024年4月22日（环球通讯社）--Anthos Therapeutics，Inc.（Anthos）是一家临床阶段公司，开发心血管疾病的创新疗法，由黑石生命科学公司（BXLS）创立，今天宣布任命比尔·默里为首席执行官兼董事会成员。

Meury joins after successfully leading Karuna Therapeutics (Karuna), which was recently acquired by Bristol Myers Squibb (BMS). During his time at Karuna, Meury led the company through a period of rapid expansion, and a transition to a fully integrated R&D and commercial organization. Meury will succeed founding CEO John Glasspool, who will join Blackstone Life Sciences as an Operating Advisor.

Meury在成功领导最近被百时美施贵宝（BMS）收购的Karuna Therapeutics（Karuna）后加入。在卡鲁纳任职期间，默里带领公司经历了一段快速扩张时期，并向完全整合的研发和商业组织过渡。默里将接替创始人兼首席执行官约翰·格拉斯普尔（JohnGlasspool），后者将加入黑石生命科学公司担任运营顾问。

Nicholas Galakatos, Ph.D., Chairman of the Board of Directors of Anthos, and Global Head of Blackstone Life Sciences, said: “Bill is a proven leader with a strong track record of advancing innovative medicines through to approval and to patients globally. We are confident that he and the Anthos team will rapidly advance the development of abelacimab to help benefit the many patients who are in need of a safer type of anticoagulant.

Anthos董事会主席兼Blackstone Life Sciences全球负责人尼古拉斯·加拉卡托斯博士说：“比尔是一位公认的领导者，在推动创新药物获得批准以及全球患者方面有着良好的记录。我们相信，他和Anthos团队将迅速推进abelacimab的开发，以帮助许多需要更安全类型抗凝剂的患者受益。

We are also grateful for John’s many contributions in getting abelacimab to achieve impressive clinical development success.” Bill Meury, incoming Anthos CEO, said: “With the highly novel Factor XI inhibitor, abelacimab, as the lead product, Anthos has quickly emerged as one of the most innovative companies in the biotech sector.

我们也感谢约翰在获得abelacimab取得令人印象深刻的临床开发成功方面所做的许多贡献。”即将上任的Anthos首席执行官比尔·默里（BillMeury）表示：“以高度新颖的XI因子抑制剂abelacimab为主导产品，Anthos迅速成为生物技术领域最具创新性的公司之一。

The opportunity to further build Anthos with Blackstone’s scale capital and potentially make a significant impact for patients with atrial fibrillation, cancer associated thrombosis and perhaps other therapeutic indications, where abelacimab may prove to be advantageous, is extremely motivating. I look forward to work.

利用Blackstone的规模资本进一步建立Anthos的机会，并可能对房颤，癌症相关血栓形成以及其他治疗适应症（abelacimab可能被证明是有利的）患者产生重大影响，这是非常令人鼓舞的。我期待着工作。